How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski

What the episode covered

Kanoski said diet, GLP-1 signaling, gut-vagus pathways, microbiome changes, and hippocampal memory are linked, with much of the mechanistic evidence coming from rodents. The register is mixed: the guest is caveated and specific, while the host packages practical takeaways inside an ad-supported wellness format. Watch whether GLP-1 brain-entry, microdosing, and gut-brain dementia work move from preclinical or anecdotal evidence into clinical results.

Our summary, written from the transcript. Not the speakers' words.

The episode, in order

1. 01GLP-1 biology and drugs

   The discussion separates endogenous GLP-1 signaling from drug-induced, super-physiological exposure and frames open questions about side effects, durability, and non-weight uses.

2. 02Brain entry and non-weight effects

   Claims about cognition, substance-use applications, and dementia depend on a mechanism the recording presents as unsettled.

3. 03Artificial sweeteners

   The signal is caution about over-translating animal data, not a direct recommendation to consume or avoid artificial sweeteners.

4. 04Diet, microbiome, and memory

   This is the central scientific throughline: food intake may shape memory systems, but much of the causal evidence discussed is preclinical.

5. 05Hunger, memory, and interoception

   The episode treats eating as a cognitive and sensory process, not only a calorie or willpower issue.

6. 06Public health and food environment

   The conversation broadens from mechanisms to institutions, but does not settle which policy or intervention would change outcomes.

Sponsors named in this episode

No sponsor named doesn't mean no ads. Each row was taken from the ad break as it was read on air. The verbatim passage behind every row is checked against the transcript character for character. Short excerpts appear below.

Roles and stated affiliations

Sponsor or conflict flagged. Health-adjacent sponsor overlap — The recording includes sponsor reads for AG1 Pro, Element, Function, Helix Sleep, and Our Place in an episode discussing nutrition, hydration, biomarkers, sleep, cooking materials, and brain health. · Commercial nature stated — Huberman states that the episode includes sponsors and the named ad reads are introduced as sponsors.

Wakewire's read of interests

• Andrew Huberman: He hosts an ad-supported science and health podcast and states that the podcast is separate from his Stanford teaching and research roles.
• Dr. Scott Kanoski: He is a USC professor whose lab studies hunger, memory, diet, the gut-brain axis, and related animal models, and he discusses his own lab's findings.
• Our Place: The sponsor sells cookware and kitchen products promoted as PFAS and toxin-free.
• Helix Sleep: The sponsor sells mattresses and pillows customized through a sleep quiz.
• AG1: The sponsor sells AG1 Pro, a supplement formula promoted with vitamins, minerals, probiotics, adaptogens, creatine, calcium HMB, and zinc carnosine.
• Element: The sponsor sells an electrolyte drink promoted for hydration and electrolyte intake.
• Function: The sponsor sells lab testing, biomarker analysis, and access to imaging.

Claims that need more support

• Kanoski said a majority of people discontinue GLP-1 treatment within two years of starting, but the episode did not provide a study or denominator.
• Huberman said PFASs are still found in 80% of nonstick pans and have been linked to major health issues, but the ad did not provide a source.

Claims made on air that the episode itself did not back up.

Questions the conversation didn't reach

• The conversation raised whether GLP-1 microdosing works or reduces side effects, and Kanoski said he was not aware of data on that.

Topics the episode did not address. This does not mean anyone avoided them.

Are you from this show? You can ask for a correction, reply, or ask us to stop coverage on the rights page.

What was said

• GLP-1 biology and drugs

  Kanoski said GLP-1 suppresses appetite, helps regulate blood glucose, and was first used clinically for diabetes before becoming widely known for weight loss.

• Brain entry and non-weight effects

  Kanoski said GLP-1 receptors are found in reward circuitry and the hippocampus, but whether newer GLP-1 drugs enter the brain and where they act remains unclear.

• Artificial sweeteners

  Kanoski said the evidence is controversial, with no definitive human answer, and described rodent work showing adult memory and metabolic changes after developmental exposure.

• Diet, microbiome, and memory

  Kanoski described rodent models in which high sugar, Western-style, junk food, or heat-treated AGE-enriched diets produced hippocampal-dependent memory impairments, sometimes persisting after diet change.

• Hunger, memory, and interoception

  Kanoski said eating-related signals reach the hippocampus through vagal and hormonal routes, and described acetylcholine release rising in the hippocampus while animals eat.

• Public health and food environment

  Huberman and Kanoski discussed obesity, ultra-processed foods, soda, hospitals, food policy, and the limits of GLP-1 drugs without nutrition and physical activity support.

Our paraphrase, not the speakers' words.

The passages we relied on

Short excerpts, credited to the show, at most 40 words each and 150 per episode. We do not publish transcripts. We link to the episode so you can hear it from the show itself.

What to watch for

• Whether the AGE-enriched diet preprint becomes a peer-reviewed paper and whether it reports the same rodent memory impairment and bacterial rescue findings. (As the preprint moves through publication.)
• Whether randomized clinical trials or peer-reviewed clinical studies test GLP-1 microdosing for appetite, side effects, cost reduction, cognition, or energy. (When clinical studies appear.)
• Whether tracer or radio-label studies show where newer GLP-1 drugs such as Ozempic or Wegovy enter the brain, if at all. (As preclinical and translational pharmacology studies publish.)
• Whether vagal nerve stimulation studies in transgenic Alzheimer's animal models report improved memory outcomes or reduced amyloid and tau pathology. (As Kanoski's lab or related groups publish results.)